A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Silke Nuber1, Chee Yeun Chung2, Daniel F Tardiff3
1Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women Hospital and Harvard Medical School, 60 Fenwood Rd, MA, 02115, Boston, US. snuber@bwh.harvard.edu.
Summary
A new drug, YTX-7739, shows promise in treating Parkinson's disease (PD) by targeting stearoyl-CoA desaturase (SCD). This inhibitor reduces toxic alpha-synuclein (αSyn) buildup, reverses neuronal damage, and improves motor function in PD models.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Parkinson's disease (PD) pathology involves toxic alpha-synuclein (αSyn) aggregates.
- Stearoyl-CoA desaturase (SCD) is implicated in αSyn-related neurodegeneration.
- YTX-7739 is an investigational, brain-penetrant SCD inhibitor.
Purpose of the Study:
- To evaluate the efficacy of YTX-7739 in preclinical Parkinson's disease models.
- To validate stearoyl-CoA desaturase (SCD) as a therapeutic target for synucleinopathies.
Main Methods:
- In vitro cell-based assays using patient-derived neurospheres and various αSyn mutations (E46K, A53T).
- In vivo studies using Parkinson's disease mouse models (3K αSyn mice).
- Assessment of αSyn pathology, neuronal survival, dopaminergic integrity, and motor function.
Main Results:
- YTX-7739 reduced αSyn-mediated neuronal death and reversed abnormal αSyn membrane interactions.
- The inhibitor decreased unsaturated fatty acids and prevented motor deficits in PD mice.
- YTX-7739 treatment restored αSyn tetramer-to-monomer ratio, dopaminergic integrity, and neuronal survival.
Conclusions:
- YTX-7739 effectively reverses pathological αSyn phenotypes in vitro and in vivo.
- Data support SCD inhibition as a viable therapeutic strategy for Parkinson's disease.
- YTX-7739 is a promising clinical candidate for treating human α-synucleinopathies.
